Company: MYSEW
Filing Date: 2025-02-10
Form Type: 424B5
Source: 0001213900-25-011767
Chunk: 1

Company: Myseum, Inc.
Filing Date: 2025-02-10
Form: 424B5
Chunk 1
---
 compensation of Benchmark will be deemed to be underwriting commissions or discounts.
We have also agreed to provide indemnification and contribution to Benchmark with respect to certain liabilities, including liabilities
under the Securities Act or the Securities Exchange Act of 1934, as amended or the Exchange Act.

As of the date of this prospectus
the aggregate market value of our outstanding common stock held by non-affiliates, or our public float, was approximately $34,522,987
based on 3,865,956 shares of outstanding common stock held by non-affiliates and a per share price of $8.93, the closing price of our
common stock on January 7, 2025 which is the highest closing price of our common stock on The Nasdaq Capital Market within the prior 60
days. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell shares pursuant to this prospectus with a value of more
than one-third of the aggregate market value of our common stock held by non-affiliates in any 12-month period, so long as the aggregate
market value of our common stock held by non-affiliates is less than $75,000,000. We have sold approximately$5,100,000 of securities pursuant to General Instruction I.B.6 of Form S-3 during the prior 12-calendar month period that ends on and includes the date of this prospectus supplement (excluding this offering) and, accordingly, may offer and sell additional shares of our common
stock having an aggregate offering price of up to approximately $6,407,662 from time to time through Benchmark in accordance with the
terms of the Sales Agreement. If our public float increases such that we may sell additional amounts under the Sales Agreement and this
prospectus, we will file an amendment to the prospectus prior to making additional sales.

Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on page S-8 of this prospectus, the accompanying prospectus, and in the reports we file with the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934, as amended, incorporated by reference into this prospectus before making a decision to invest in our common stock.

Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus or the accompanying prospectus. Any representation to the contrary is